Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by TFG Asset Management GP Ltd

TFG Asset Management GP Ltd grew its position in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 78.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,400,000 shares of the company's stock after buying an additional 615,645 shares during the quarter. Annexon accounts for 1.5% of TFG Asset Management GP Ltd's holdings, making the stock its 18th largest holding. TFG Asset Management GP Ltd owned approximately 1.31% of Annexon worth $7,182,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Sphera Funds Management LTD. purchased a new position in Annexon in the fourth quarter valued at $6,377,000. Ameriprise Financial Inc. boosted its holdings in Annexon by 483.6% in the fourth quarter. Ameriprise Financial Inc. now owns 926,642 shares of the company's stock valued at $4,754,000 after purchasing an additional 767,869 shares during the period. Vanguard Group Inc. boosted its holdings in Annexon by 11.6% in the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company's stock valued at $28,456,000 after purchasing an additional 576,625 shares during the period. Mutual of America Capital Management LLC boosted its holdings in Annexon by 56.2% in the fourth quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company's stock valued at $5,282,000 after purchasing an additional 370,426 shares during the period. Finally, Candriam S.C.A. lifted its holdings in Annexon by 15.6% during the 4th quarter. Candriam S.C.A. now owns 2,534,230 shares of the company's stock worth $13,001,000 after buying an additional 341,431 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have issued reports on the company. HC Wainwright decreased their price target on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Needham & Company LLC decreased their price target on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th.

Annexon Trading Down 4.4%

Shares of Annexon stock traded down $0.10 on Friday, hitting $2.09. The stock had a trading volume of 1,684,689 shares, compared to its average volume of 1,781,470. Annexon, Inc. has a 52-week low of $1.29 and a 52-week high of $7.85. The stock has a market cap of $228.75 million, a price-to-earnings ratio of -1.98 and a beta of 1.24. The company's 50 day moving average price is $1.82 and its 200 day moving average price is $3.35.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). Analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.